# Zealand Pharma Reports Positive Phase 2 Trial Results for Weight-Loss Drug Petrelintide

- URL: https://stocks.freetheai.org/news/zealand-pharma-reports-positive-phase-2-trial-results-for-weight-loss-drug-641712
- Published: 2026-10-07T17:14:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [OMXCOP:ZEAL](https://stocks.freetheai.org/symbols/OMXCOP-ZEAL)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Zealand Pharma A/S (OMXCOP:ZEAL) announced successful results from its Phase 2b clinical trial, ZUPREME-2, which evaluated its drug candidate petrelintide. The 28-week study involving 220 participants met its primary goal, showing that patients achieved a mean weight loss of up to 9.2%, compared to a 2.0% reduction for those on a placebo. Additionally, the drug demonstrated placebo-adjusted HbA1c reductions of 0.61% to 0.88%, indicating improved blood sugar control.

The results support the potential competitiveness of petrelintide in treating obesity and type 2 diabetes. The treatment also demonstrated a favorable safety profile with no unexpected adverse signals. Discontinuations due to gastrointestinal issues were low, affecting 1.9% of patients on the drug compared to 1.7% in the placebo group, which could support patient adherence.

Following these mid-stage findings, Zealand Pharma has initiated a Phase 3 trial program alongside Roche. Market observers will watch for longer-term data from these upcoming trials, specifically regarding cardiovascular and metabolic outcomes, which will be essential to evaluate the drug's full clinical value and commercial potential.

## Key points

- Zealand Pharma's Phase 2b trial of petrelintide met its primary endpoint, showing a mean weight loss of up to 9.2% compared to 2.0% for the placebo at 28 weeks.
- The drug demonstrated placebo-adjusted HbA1c reductions ranging from 0.61% to 0.88%, indicating improved glycemic control.
- Tolerability was high, with gastrointestinal side effect discontinuation rates at 1.9% for petrelintide versus 1.7% for the placebo.
- Zealand Pharma has initiated a Phase 3 clinical trial program for petrelintide in partnership with Roche.

## Questions and answers

### What were the results of the Zealand Pharma ZUPREME-2 trial?

The ZUPREME-2 Phase 2b trial of petrelintide met its primary endpoint, showing up to 9.2% mean weight loss compared to 2.0% for a placebo over 28 weeks. It also showed placebo-adjusted HbA1c reductions of 0.61% to 0.88% and had no unexpected safety signals.

### Did petrelintide show any significant side effects in Phase 2?

No unexpected safety signals were reported in the trial. Discontinuations due to gastrointestinal adverse events were low, occurring in 1.9% of patients taking petrelintide compared to 1.7% of patients on the placebo.

### What is the next step for Zealand Pharma's petrelintide?

Zealand Pharma has initiated a Phase 3 clinical program for petrelintide in partnership with Roche. Future milestones will include larger, longer-term trials evaluating the drug's efficacy, tolerability, and cardiovascular or metabolic outcomes.